Cancer Res Treat.  2005 Apr;37(2):79-86.

Chemotherapy for Advanced Gastric Cancer: Slow but Further Progress

Affiliations
  • 1Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. yhk0215@korea.ac.kr

Abstract

Gastric cancer remains a significant problem in terms of global health, and is the most common cancer in Korea. Surgery is the only potentially curative treatment for localized gastric cancer, but most cases present at an advanced stage. Randomized trials have demonstrated that chemotherapy for advanced gastric cancer improves the quality of life and extends survival, by 4~6 months, compared with best supportive care alone. Single agents with a proven activity in a first-line setting include 5-fluorouracil (5-FU), doxorubicin, mitomycin C, cisplatin, taxanes (docetaxel and paclitaxel) and oral fluoropyrimidines (capecitabine and TS-1). Based on the results from several large scale randomized trials, FP (5-FU/cisplatin) and ECF (epirubicin/cisplatin/5-FU) combinations are the most widely used regimen against advanced gastric cancer. Phase II studies of the FP and ECF combination reported a 40~51% response rate in previously untreated patients, and this regimen also produced a significantly higherresponse rate than the FAM (5-FU/doxorubicin/ mitomycin) and FAMTX (5-FU/doxorubicin/methotrexate) regimens, respectively. However, significant treatment related- toxicities and discomfort were reported from ECF, which prevents this combination from becoming the standard treatment regimen. While no one combination chemotherapy regimen is accepted as the standard for advanced gastric cancer, FP is currently considered a suitable reference regimen worldwide. New agents, such as taxane, irinotecan and oxaliplatin, combined with old agents, such as cisplatin and 5-FU, are currently under evaluation to further improve treatment outcomes. Also, oral 5-FU prodrugs are replacing the cumbersome 5-FU long-term infusion due to its convenience and superior toxicity profile. However, the low complete response rate and short response duration are still the main obstacles in the chemotherapy for gastric cancer. Only large scale comparative clinical trials will give clues to improve the results of gastric cancer treatments.

Keyword

Chemotherapy; Stomach neoplasm; Palliative treatment; Review

MeSH Terms

Cisplatin
Doxorubicin
Drug Therapy*
Drug Therapy, Combination
Fluorouracil
Humans
Korea
Mitomycin
Palliative Care
Prodrugs
Quality of Life
Stomach Neoplasms*
Taxoids
Cisplatin
Doxorubicin
Fluorouracil
Mitomycin
Prodrugs
Taxoids

Reference

1. Shin HR, Jung KW, Won YJ, Park JG. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat. 2004; 36:103–114.
Article
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000; 50:7–33. PMID: 10735013.
Article
3. Glimelius B, Ekstrom K, Hoffman K, Grat W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8:163–168. PMID: 9093725.
Article
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587–591. PMID: 7533517.
Article
5. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993; 72:37–41. PMID: 8508427.
Article
6. Ajani JA. Standard chemotherapy for gastric carcinoma: Is it a myth? J Clin Oncol. 2000; 18:4001–4003.
Article
7. Comis RL, Carter SK. A review of chemotherapy in gastric cancer. Cancer. 1974; 34:1576–1586. PMID: 4279136.
Article
8. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003; 21:54–59. PMID: 12506170.
Article
9. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71:3813–3818. PMID: 8508349.
10. Johnson PW, Thompson PI, Seymour MT, Deasy NP, Thuraisingham RC, Slevin ML, et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer. 1991; 64:603–605. PMID: 1911206.
Article
11. Louvet C, de Gramont A, Demuynck B, Nordlinger B, Maisani JE, Lagadec B, et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol. 1991; 2:229–230. PMID: 2043494.
Article
12. Arbuck SG, Douglass HO Jr, Trave F, Milliron S, Baroni M, Nava H, et al. A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol. 1987; 5:1150–1156. PMID: 3498014.
Article
13. Moertel CG, Lavin PT. Eastern Cooperative Oncology Group. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rev. 1979; 63:1863–1869.
14. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev. 1988; 15:257–277. PMID: 3071419.
Article
15. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998; 4:269–274. PMID: 9689986.
16. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998; 9:307–310. PMID: 9635920.
Article
17. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998; 21:416–419. PMID: 9708646.
Article
18. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996; 13:87–93. PMID: 9013471.
Article
19. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan To Kagaku Ryoho. 1999; 26:487–496. PMID: 10097745.
20. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho. 1998; 25:1915–1924. PMID: 9797814.
21. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol. 2002; 32:248–254. PMID: 12324575.
Article
22. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994; 86:836–842. PMID: 8182764.
Article
23. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989; 49:5077–5082. PMID: 2548710.
24. Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. 2003; 89:997–1001. PMID: 12966415.
Article
25. Lin-Shin L, Hecht J. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol. 2000; 19:289a. (abst 1130).
26. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. CPT-11 Gastrointestinal Cancer Study Group. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Gan To Kagaku Ryoho. 1994; 21:1033–1038. PMID: 8210254.
27. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1988; 22:333–338. PMID: 3139315.
Article
28. Kim YH, Cheong SK, Lee JD, Park JS, Shin SW, Kim JS, et al. Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol. 1996; 19:212–216. PMID: 8610653.
Article
29. Ravaud A, Borner M, Schellens JH, Geoffrois L, Schoffski P, Wanders J, et al. UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. Oncology (Huntingt). 1999; 13(7):Suppl 3. 61–63. PMID: 10442364.
30. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34:1274–1281. PMID: 9849491.
Article
31. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000; 45(4):291–297. PMID: 10755317.
32. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004; 15:1344–1347. PMID: 15319239.
Article
33. Kondo K, Chin K, Sakamoto J, Kojima H, Terashima M, Yamamura Y, et al. A multicenter phase II trial using 4-week cycles of capecitabine in advanced/metastatic gastric cancer (AGC). Proc Am Soc Clin Oncol. 2003; 22:321. (Abstr).
34. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996; 7:548–557. PMID: 8862723.
Article
35. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998; 34:1715–1720. PMID: 9893658.
36. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000; 58:191–197. PMID: 10765119.
37. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer. 2003; 39:1264–1270. PMID: 12763215.
38. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003; 21:54–59. PMID: 12506170.
Article
39. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol. 2003; 14(Suppl 2):ii49–ii55. PMID: 12810459.
Article
40. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991; 9:827–831. PMID: 2016625.
Article
41. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989; 7:1310–1317. PMID: 2671287.
Article
42. Lerner A, Gonin R, Steele GD Jr, Mayer RJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol. 1992; 10:536–540. PMID: 1548518.
Article
43. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992; 10:541–548. PMID: 1548519.
Article
44. O'Connell MJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited. J Clin Oncol. 1992; 10:515–516. PMID: 1548514.
45. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000; 18:2648–2657. PMID: 10894863.
Article
46. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol. 2003; 14:1258–1263. PMID: 12881389.
Article
47. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994; 5:609–616. PMID: 7993836.
Article
48. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15:261–267. PMID: 8996151.
Article
49. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002; 20:1996–2004. PMID: 11956258.
Article
50. Lacave AJ, Baron FJ, Anton LM, Estrada E, DeSande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol. 1991; 2:751–754. PMID: 1801881.
Article
51. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer. 1994; 30A:1263–1269. PMID: 7999410.
Article
52. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71:3813–3818. PMID: 8508349.
Article
53. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999; 15:295–301. PMID: 10023695.
Article
54. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999; 22:580–586. PMID: 10597742.
55. Kornek GV, Raderer M, Schull B, Fiebiger W, Gedlicka C, Lenauer A, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer. 2002; 86:1858–1863. PMID: 12085176.
Article
56. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001; 12:47–51. PMID: 11249048.
Article
57. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Swiss Group for Clinical Cancer Research (SAKK). European Institute of Oncology (EIO). Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol. 2000; 11:301–306. PMID: 10811496.
Article
58. Schull B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, et al. Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Oncology. 2003; 65:211–217. PMID: 14657594.
Article
59. Roth AD, Maibach R, Fazio N, Cessa C, Stupp R, Morant R, et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)- cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol. 2004; 15:759–764. PMID: 15111343.
60. Ajani JA, Fodor M, Van Cutsem E, Tjulandin S, Moiseyenko V, Cabral F, et al. Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol. 2000; 19:247a. (Abstr).
61. Ajani JA, VanCutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol. 2003; 22:249. (Abstr).
62. Oh SC, Park KH, Choi IK, Yoon SY, Kim SJ, Seo JH, et al. Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. Br J Cancer. 2005; 92:827–831. PMID: 15726097.
Article
63. Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, et al. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer. 2004; 91:18–22. PMID: 15188010.
Article
64. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004; 15:1773–1781. PMID: 15550582.
Article
65. Bugat R. Irinotecan in the treatment of gastric cancer. Ann Oncol. 2003; 14(Suppl 2):ii37–ii40. PMID: 12810456.
Article
66. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol. 1997; 15:921–927. PMID: 9060529.
Article
67. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999; 17:319–323. PMID: 10458249.
Article
68. Shimada S, Yagi Y, Kuramoto M, Aoki N, Ogawa M. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep. 2003; 10:687–691. PMID: 12684644.
69. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002; 20:2031–2037. PMID: 11956262.
Article
70. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002; 20:4543–4548. PMID: 12454110.
Article
71. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer. 2004; 91:453–458. PMID: 15226770.
Article
72. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004; 22:658–663. PMID: 14966088.
Article
73. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol. 2003; 14:383–387. PMID: 12598342.
Article
74. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol. 2004; 15:1204–1209. PMID: 15277259.
Article
75. Sumpter KA, Harper-Wynne C, Cunningham D, Oates J, Tebbutt N, Iveson T, et al. Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation of dose escalation. Proc Am Soc Clin Oncol. 2003; 22:257. (Abstr).
76. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002; 13:1893–1898. PMID: 12453857.
Article
77. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer. 2005; 92:246–251. PMID: 15655540.
Article
78. Chun JH, Kim HK, Lee JS, Choi JY, Hwangbo B, Lee HG, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol. 2005; 28:188–194. PMID: 15803015.
Article
79. Park YH, Ryoo BY, Choi SJ, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 2004; 90:1329–1333. PMID: 15054450.
Article
80. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003; 89:2207–2212. PMID: 14676796.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr